Physician profile
Kim Phan
NPI 1043934706
$4,268.66
in general payments reported to CMS, 2019-2025
23 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $1,499 · 2024: $1,590 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017 · Education: $98.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.23 |
| Education | $98.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,818.09 | 2022-2025 | |
| Incyte Corporation | $464.51 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $322.33 | 2023-2025 | Ilumya |
| Galderma Laboratories, L.P. | $273.66 | 2023-2025 | Nemluvio, Dysport |
| Pfizer INC. | $267.48 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.63 | 2023-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $245.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.11 | 2023-2025 | Sotyktu |
| Amgen INC. | $80.24 | 2024 | Otezla |
| Lilly USA, LLC | $47.04 | 2024-2025 | Ebglyss, Taltz |
| Almirall LLC | $41.83 | 2025 | Klisyri |
| Leo Pharma INC. | $29.86 | 2024 | Adbry |
| Dermavant Sciences, INC. | $28.71 | 2023 | Vtama |
| Ucb, INC. | $25.39 | 2025 | Bimzelx |
| Revance Therapeutics, INC. | $24.11 | 2025 | Daxxify |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $24.04 | 2024 | Ycanth |
| Lnhc, INC | $23.89 | 2025 | Zelsuvmi |
| Novo Nordisk INC | $22.91 | 2023 | Saxenda, Wegovy |
| Arcutis Biotherapeutics, INC. | $22.52 | 2025 | Zoryve |
| Solta Medical, A Division of Bausch Health US, LLC | $20.44 | 2025 | |
| Strata Skin Sciences, INC. | $16.96 | 2025 | Xtrac |
| Janssen Biotech, INC. | $16.00 | 2024 | Tremfya |
| Biofrontera INC. | $9.97 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.